Alteogen's competitive edge unaffected by Samsung Biologics' SC tech, says Hana Securities

Hana Securities has dismissed recent market concerns suggesting that Samsung Biologics' acquisition of subcutaneous (SC) formulation technology could undermine Alteogen's competitive edge. The securities firm argues that these fears are overstated and that Alteogen's market position remains robust.

Analysts at Hana Securities noted that Samsung Biologics' SC technology appears to be a mere replication of the U.S.-based Halozyme Therapeutics' established 'ENHANZE' platform. This observation suggests that Samsung Biologics has not developed a novel or disruptive technology, but rather is utilizing an existing framework.

Consequently, Hana Securities believes that the emergence of a biosimilar SC formulation from Samsung Biologics will not significantly impact Alteogen's technological competitiveness. The firm maintains its investment recommendation, emphasizing that Alteogen's existing patent barriers continue to provide effective protection for its proprietary technologies. The firm's assessment suggests Alteogen's unique advantages remain intact despite the new market entrant.